LCTX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...

Stats
Šios dienos apimtis	602 177
Vidutinė apimtis	947 408
Rinkos kapitalizacija	200.13M
EPS	$0 ( 2024-03-07 )
Kita pelno data	( $-0.0400 ) 2024-05-09
Last Dividend	$0.0800 ( 2003-12-15 )
Next Dividend	$0 ( N/A )
P/E	-8.83
ATR14	$0.00500 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Culley Brian M	Buy	1 900 000	Employee Stock Option (Right to Buy)
2024-03-07	Samuel George A. Iii	Buy	650 000	Employee Stock Option (Right to Buy)
2024-03-07	Howe Jill Ann	Buy	650 000	Employee Stock Option (Right to Buy)
2024-02-11	Samuel George A. Iii	Sell	6 076	Restricted Stock Units
2024-02-11	Samuel George A. Iii	Buy	6 076	Common Shares, no par value

INSIDER POWER
98.16
Last 93 transactions
Buy: 20 710 358 \| Sell: 1 476 683

Tūris Koreliacija

Ilgas: -0.40 (neutral)

Trumpas: 0.00 (neutral)

Signal:(38.24) Neutral

Lineage Cell Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Lineage Cell Therapeutics Koreliacija - Valiuta/Žaliavos

0.24
( neutral )

0.55
( weak )

0.00
( neutral )

-0.58
( weak negative )

0.58
( weak )

Lineage Cell Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$8.95M
Bruto pelnas:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2023
Pajamos:	$8.95M
Bruto pelnas:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2022
Pajamos:	$14.70M
Bruto pelnas:	$13.98M (95.05 %)
EPS:	$-0.160

FY	2021
Pajamos:	$3.90M
Bruto pelnas:	$2.47M (63.40 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Lineage Cell Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0800	2003-12-15
Last Dividend	$0.0800	2003-12-15
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0800	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-04)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NOG	Ex Dividend Knight	2023-09-27	Quarterly	0.00%
CLM	Ex Dividend Knight	2023-10-13	Monthly	0.00%
GLO	Ex Dividend Knight	2023-09-21	Monthly	0.00%
VERS	Ex Dividend Junior	2023-06-21	Quarterly	0.00%
BRN	Ex Dividend Junior	2023-08-23	Sporadic	0.00%
FAX	Ex Dividend King	2023-09-21	Monthly	0.00%
NBO	Ex Dividend Knight	2023-09-28	Monthly	0.00%
SEB	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
AVSU	Ex Dividend Junior	2023-09-21	Quarterly	0.00%
EPM	Ex Dividend Knight	2023-09-21	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.213	1.200	-7.10	-8.52	[0 - 0.3]
returnOnEquityTTM	-0.313	1.500	-4.59	-6.89	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.14	0.800	4.30	3.44	[1 - 3]
quickRatioTTM	2.02	0.800	2.84	2.27	[0.8 - 2.5]
cashRatioTTM	1.973	1.500	0.148	0.222	[0.2 - 2]
debtRatioTTM	0.0292	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	56.86	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0847	-0.169	[0 - 20]
debtEquityRatioTTM	0.0465	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.905	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-2.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-9.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0885	0.800	-2.74	-2.19	[0.5 - 2]
Total Score				-0.295

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-8.43	1.000	-0.952	0	[1 - 100]
returnOnEquityTTM	-0.313	2.50	-2.95	-6.89	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0564	-0.169	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0546	1.500	-2.97	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.19	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.30

Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Realaus laiko atnaujinimai Lineage Cell Therapeutics [LCTX]

Upcoming Earnings Alert

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for AMEX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)